Jayden Martinez represents private and publicly held companies in a range of corporate and securities matters, including private financings, initial public offerings, mergers and acquisitions, SEC reporting and compliance and corporate governance.
Cooley advised RayzeBio, a targeted radiopharmaceutical company developing an innovative pipeline against solid tumor targets, on its upsized $357.6 million initial public offering.
TriSalus Life Sciences Completes Merger With MedTech Acquisition Corporation
August 16, 2023
Cooley advised TriSalus Life Sciences, an oncology company with a focus on treatments for patients with liver and pancreatic tumors, on its merger with MedTech Acquisition Corporation.
Cooley represented Shoreline Biosciences, a biotechnology company developing cellular immunotherapies, on its $140 million financing led by Ally Bridge Group. Partner Tom Coll led the Cooley team.
Cooley advised Longboard Pharmaceuticals on its $80 million initial public offering of 5,000,000 shares of common stock. Longboard Pharmaceuticals, whose securities now trade on the Nasdaq Global Market under the symbol LBPH, is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Partners Steven Przesmicki and Charlie Kim led the Cooley team.
